Kaken Pharmaceutical Co (TSE:4521) Additional Paid-In Capital : 円11,462 Mil(As of Dec. 2023)

View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co Additional Paid-In Capital?

Kaken Pharmaceutical Co's quarterly additional paid-in capital increased from Jun. 2023 (円11,406 Mil) to Sep. 2023 (円11,462 Mil) but then stayed the same from Sep. 2023 (円11,462 Mil) to Dec. 2023 (円11,462 Mil).

Kaken Pharmaceutical Co's annual additional paid-in capital stayed the same from Mar. 2021 (円11,406 Mil) to Mar. 2022 (円11,406 Mil) and stayed the same from Mar. 2022 (円11,406 Mil) to Mar. 2023 (円11,406 Mil).

Kaken Pharmaceutical Co Additional Paid-In Capital Historical Data

The historical data trend for Kaken Pharmaceutical Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Additional Paid-In Capital Chart

Kaken Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Additional Paid-In Capital

Get a 7-Day Free Trial

11,408.00

11,406.00

Kaken Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															11,406.00	11,406.00	11,406.00	11,462.00	11,462.00

Kaken Pharmaceutical Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Kaken Pharmaceutical Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Kaken Pharmaceutical Co (TSE:4521) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

KKPCF:USA

Address

28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650

Website

http://www.kaken.co.jp

Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines